The course of COVID-19 in a multiple sclerosis: a case report

Area of Science:

• Immunology
• Neurology
• Infectious Diseases

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Disease-modifying therapies (DMTs) are crucial for managing MS, with anti-CD20 monoclonal antibodies representing a highly effective treatment class.
• Immunosuppression induced by certain MS DMTs can impact patients' susceptibility to infections.

Observation:

• A 37-year-old patient with MS on ublituximab (anti-CD20) therapy experienced a protracted, relapsing-remitting course of COVID-19.
• The patient developed a secondary bacterial infection during the prolonged COVID-19 illness.
• This clinical presentation suggests a potential link between anti-CD20 therapy and complicated viral infections.

Findings:

• Anti-CD20 monoclonal antibody therapy in MS patients may be associated with an increased incidence and severity of COVID-19.
• The immunosuppressive effects of anti-CD20 agents can lead to a wave-like or protracted course of viral infections.
• Such immunosuppression creates a favorable environment for secondary bacterial and fungal co-infections in patients with COVID-19.

Implications:

• Clinicians should consider the risk of prolonged and complicated COVID-19 in multiple sclerosis patients undergoing anti-CD20 immunotherapy.
• Careful monitoring for secondary infections is essential in this patient population.
• Further research is warranted to elucidate the mechanisms and optimize treatment strategies for COVID-19 in immunocompromised MS patients.